Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENOV Stock Forecast 2025-2026
$32.37
Current Price
$1.86B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ENOV Price Targets
+131.7%
To High Target of $75.00
+73.0%
To Median Target of $56.00
+14.3%
To Low Target of $37.00
ENOV Price Momentum
-10.2%
1 Week Change
-4.2%
1 Month Change
-35.3%
1 Year Change
-26.2%
Year-to-Date Change
-36.7%
From 52W High of $51.10
+10.4%
From 52W Low of $29.32
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Enovis (ENOV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ENOV and similar high-potential opportunities.
Latest ENOV Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, ENOV has a bullish consensus with a median price target of $56.00 (ranging from $37.00 to $75.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $32.37, the median forecast implies a 73.0% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Caitlin Cronin at Canaccord Genuity, projecting a 131.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENOV Analyst Ratings
10
Buy
1
Hold
0
Sell
ENOV Price Target Range
Low
$37.00
Average
$56.00
High
$75.00
Current: $32.37
Latest ENOV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENOV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $70.00 |
| May 9, 2025 | Needham | Mike Matson | Buy | Maintains | $57.00 |
| May 9, 2025 | JMP Securities | David Turkaly | Market Outperform | Maintains | $55.00 |
| Apr 9, 2025 | Needham | Mike Matson | Buy | Reiterates | $64.00 |
| Apr 2, 2025 | Needham | Mike Matson | Buy | Reiterates | $64.00 |
| Feb 27, 2025 | Needham | Mike Matson | Buy | Maintains | $64.00 |
| Nov 7, 2024 | Needham | Mike Matson | Buy | Reiterates | $65.00 |
| Oct 3, 2024 | JMP Securities | David Turkaly | Market Outperform | Initiates | $62.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $58.00 |
| Aug 8, 2024 | JP Morgan | Robbie Marcus | Neutral | Maintains | $50.00 |
| Aug 8, 2024 | Needham | Mike Matson | Buy | Maintains | $65.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $62.00 |
| Jun 13, 2024 | JP Morgan | Robbie Marcus | Neutral | Initiates | $53.00 |
| May 3, 2024 | Needham | Mike Matson | Buy | Reiterates | $82.00 |
| Apr 10, 2024 | Needham | Mike Matson | Buy | Reiterates | $82.00 |
| Feb 23, 2024 | Needham | Mike Matson | Buy | Maintains | $82.00 |
| Feb 23, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $75.00 |
| Feb 23, 2024 | Wells Fargo | Vik Chopra | Overweight | Maintains | $79.00 |
| Feb 13, 2024 | Stephens & Co. | George Sellers | Overweight | Initiates | $72.00 |
| Jan 22, 2024 | UBS | Danielle Antalffy | Buy | Initiates | $75.00 |
Enovis Corporation (ENOV) Competitors
The following stocks are similar to Enovis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enovis Corporation (ENOV) Financial Data
Enovis Corporation has a market capitalization of $1.86B with a P/E ratio of -2.2x. The company generates $2.15B in trailing twelve-month revenue with a -37.6% profit margin.
Revenue growth is +8.2% quarter-over-quarter, while maintaining an operating margin of +0.9% and return on equity of -27.4%.
Valuation Metrics
Market Cap
$1.86B
Enterprise Value
$3.39B
P/E Ratio
-2.2x
PEG Ratio
10.3x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+8.2%
Gross Margin
+59.5%
Operating Margin
+0.9%
Net Margin
-37.6%
EPS Growth
+8.2%
Financial Health
Cash/Price Ratio
+2.1%
Current Ratio
2.6x
Debt/Equity
55.7x
ROE
-27.4%
ROA
+0.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Enovis Corporation (ENOV) Business Model
About Enovis Corporation
What They Do
Develops innovative medical technology solutions.
Business Model
Enovis Corporation generates revenue by supplying a diverse range of medical equipment and technology solutions to healthcare providers, including hospitals and clinics. Its products focus on improving patient outcomes in sectors like orthopedics, pain management, and wound care, thereby catering to the needs of both healthcare professionals and patients.
Additional Information
The company emphasizes research and development to drive innovation in the healthcare industry, positioning itself as a key player in enhancing surgical efficiencies and patient recovery. This commitment to advancing medical science not only benefits patient care but also strengthens its market presence.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,367
CEO
Mr. Matthew L. Trerotola
Country
United States
IPO Year
2022
Website
www.enovis.comEnovis Corporation (ENOV) Latest News & Analysis
Latest News
Quick Summary
Enovis Corporation (NYSE:ENOV) will hold its Q1 2025 Earnings Conference Call on May 8, 2025, at 8:30 AM ET, featuring key executives and financial analysts.
Why It Matters
The Q1 2025 earnings call for Enovis Corporation provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Enovis Announces First Quarter 2025 Results
15 days ago
Quick Summary
Enovis Corporation reported 8% sales growth in Q1 2025, with Reconstructive sales up 11%. Damien McDonald will become CEO on May 12, 2025. An investor call is scheduled for today at 8:30 am ET.
Why It Matters
Strong sales growth and improved EBITDA margins signal financial health and operational efficiency for Enovis, potentially boosting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enovis (ENOV) reported Q3 earnings of $0.81 per share, surpassing the Zacks estimate of $0.74 and up from $0.50 per share year-over-year.
Why It Matters
Enovis's earnings beat expectations and show significant year-over-year growth, indicating strong company performance and potential for stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Enovis Corporation (NYSE: ENOV) will host an investor conference call on May 8, 2025, at 8:30 a.m. ET to discuss Q1 2025 financial results, with an earnings release issued that morning.
Why It Matters
Enovis' upcoming investor call will reveal Q1 2025 financial results, influencing stock valuation based on performance insights and future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enovis Corporation has appointed Damien McDonald as CEO, effective May 12, 2025, succeeding Matt Trerotola. Q1 revenue is projected between $555-$563 million, with adjusted EBITDA of $97-$100 million.
Why It Matters
Leadership changes can impact company strategy and performance. Enovis' revenue and EBITDA forecasts indicate stability, but the new CEO's direction will be crucial for future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enovisâ„¢ (NYSE: ENOV) will showcase its foot and ankle solutions at the ACFAS Annual Scientific Conference in Phoenix, AZ, from March 27-30, 2025.
Why It Matters
Enovis' showcase at ACFAS highlights its innovation in foot and ankle solutions, potentially driving growth and investor interest in the medical technology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ENOV Stock
What is Enovis Corporation's (ENOV) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Enovis Corporation (ENOV) has a median price target of $56.00. The highest price target is $75.00 and the lowest is $37.00.
Is ENOV stock a good investment in 2025?
According to current analyst ratings, ENOV has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $32.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENOV stock?
Wall Street analysts predict ENOV stock could reach $56.00 in the next 12 months. This represents a 73.0% increase from the current price of $32.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enovis Corporation's business model?
Enovis Corporation generates revenue by supplying a diverse range of medical equipment and technology solutions to healthcare providers, including hospitals and clinics. Its products focus on improving patient outcomes in sectors like orthopedics, pain management, and wound care, thereby catering to the needs of both healthcare professionals and patients.
What is the highest forecasted price for ENOV Enovis Corporation?
The highest price target for ENOV is $75.00 from Caitlin Cronin at Canaccord Genuity, which represents a 131.7% increase from the current price of $32.37.
What is the lowest forecasted price for ENOV Enovis Corporation?
The lowest price target for ENOV is $37.00 from at , which represents a 14.3% increase from the current price of $32.37.
What is the overall ENOV consensus from analysts for Enovis Corporation?
The overall analyst consensus for ENOV is bullish. Out of 17 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $56.00.
How accurate are ENOV stock price projections?
Stock price projections, including those for Enovis Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:53 AM UTC